Get started
Author

Mike Whelan

Observed names: M A Whelan, M Whelan, M. A. Whelan, M. Whelan, M.A Whelan, M.A. WHELAN, M.A. Whelan
OpenAlex ID: A5109574929
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate‐pulsed cells: a phase I/II study
2004 · Hardev S. Pandha, Robert J. John, et al. · British Journal of Urology · 109
Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response
2003 · C. Rollier, E. Depla, et al. · Journal of Virology · 93
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity
2007 · Christine S. Rollier, Glaucia Paranhos-Baccala, et al. · Hepatology · 92
PDF
Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer
2002 · J.D. Eaton, M.J.A. Perry, et al. · British Journal of Urology · 74
An Interleukin-10 Promoter Polymorphism May Influence Tumor Development in Renal Cell Carcinoma
2005 · E. HAVRANEK, W.M. HOWELL, et al. · The Journal of Urology · 38
Cancer vaccines as a therapeutic modality: the long trek
2006 · A. G. Dalgleish, M. A. Whelan · Cancer Immunology Immunotherapy · 36
PDF
Cancer immunotherapy: an embarrassment of riches?
2003 · Mike Whelan, Joseph Whelan, et al. · Drug Discovery Today · 33
Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease
2013 · D C Macdonald, H Singh, et al. · Mucosal Immunology · 22
PDF
Allogeneic Tumor–Dendritic Cell Fusion Vaccines for Generation of Broad Prostate Cancer T-Cell Responses
2004 · Andreas Lundqvist, Andreas Palmborg, et al. · Medical Oncology · 21
Biomarkers for the Development of Cancer Vaccines
2006 · John Copier, Mike Whelan, et al. · Molecular Diagnosis & Therapy · 20
Sulphydryl reactivity of the HLA-B27 epitope: accessibility of the free cysteine studied by flow cytometry.
1992 · L MacLean, M Macey, et al. · Annals of the Rheumatic Diseases · 20
PDF
Effect of a Free Sulphydryl Group on Expression of HLA-B27 Specificity
1990 · J. R. Archer, M. A. Whelan, et al. · Scandinavian Journal of Rheumatology · 16
Advances in prostate cancer immunotherapy
2002 · E.G. Havranek, M.A. Whelan, et al. · Surgical Oncology · 14
The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model
2005 · Marie-Christine Labarthe, Nicole Halanek, et al. · Cancer Immunology Immunotherapy · 13
A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action
2008 · A J MacDonald, N A Libri, et al. · Clinical & Experimental Immunology · 11
A novel murine model of allogeneic vaccination against prostate cancer
2007 · M.-C. Labarthe, P. Theocharous, et al. · Cancer Immunology Immunotherapy · 10
The effect of whole cell allogeneic vaccination on the progression of hormone-relapsed prostate cancer
2004 · H. S. Pandha, A. Michael, et al. · Journal of Clinical Oncology · 10
HLA-B27 subtypes
1991 · I.L. Maclean, J.R. Archer, et al. · The Lancet · 6
Novel immunotherapeutic approaches to prostate cancer.
2005 · Angus Dalgleish, Mike Whelan · PubMed · 4
Biomarkers for Development of Cancer Vaccines
2006 · Mike Whelan, Graham Ball, et al. · Personalized Medicine · 1
HLA-B27 and effector T cells: arthritogenic peptide or arthritogenic antigen?
1993 · J.R. Archer, M.A. Whelan · The Lancet · 1
A Dual Insert Hepatitis B Tandem Core Vaccine Elicits Strong Hbv Immune Responses and Simultaneously Confers Protective Immunity in an Influenza Model
2010 · Mike Whelan, Aadil El-Turabi, et al. · UCL Discovery (University College London)
P76 Lentiviral vectors co-expressing hepatitis B core and vFLIP induce potent CD8 T-cell and antibody responses in HLA-A2 transgenic mice
2010 · D Macdonald, N Brindle, et al. · Gut
Immunological response patterns correlate with clinical outcome after allogeneic vaccination in hormone resistant prostate cancer metastatic to bone
2007 · G Balls, N. Quatan, et al. · Open Research (University of Surrey)
260 Allogeneic whole cell vaccination significantly delays disease progression in hormone-relapsed prostate cancer: final data from a phase II study
2004 · A. Michael, N. Quatan, et al. · European Journal of Cancer Supplements
Works count: 34
Citation count: 644
H-index: 13
I10-index: 17
Year
Topic
Type